Chief Scientific Officer

Philip is a serial entrepreneur, building companies that develop new therapies for neurological diseases. Leveraging over 20 years of experience in cell and gene therapy, Philip has developed iPSC -derived cell products to treat Type 1 diabetes, neurodegenerative diseases and liver diseases at Smith Therapeutics, AZTherapies, Sigilon Therapeutics and Flagship Pioneering.

Senior Clinical Advisor

Dr. David J. Altschul, MD, FAANS, FCNS, serves as the Chief of the Division of Cerebrovascular Neurosurgery, Surgical Director of the Comprehensive Stroke Center, Associate Residency Program Director, and Professor of Neurosurgery and Radiology at Montefiore-Einstein. He is a dual trained open-endovascular neurosurgeon, having completed his neurosurgical residency at Montefiore-Einstein and a neuroendovascular fellowship under the guidance of Dr. Alejandro Berenstein at Mt. Sinai.

Throughout his esteemed career, Dr. Altschul has garnered recognition for his exceptional patient care and unwavering commitment to excellence in neurovascular surgery. Renowned for his innovative treatment approach, he leverages cutting-edge technology and research to ensure optimal care for his patients. Actively engaged in numerous research initiatives focusing on new device developments and clinical trials, he has established a thriving Cerebrovascular research lab at Montefiore-Einstein. Dr. Altschul takes great pride in his dedication to mentorship, consistently offering his time to guide students at various stages of their learning journeys.

SENIOR TISSUE ENGINEER

Wyndham began his scientific career studying Physics at the College of William & Mary in Williamsburg, VA; it was during this time that he had his first experience conducting research in biology and biophysics. Following his interest in applying techniques from the physical sciences to the biological world, Wyndham then completed his PhD in Biomedical Engineering at the University of Miami under Dr. Noel Ziebarth, where he was awarded the Graduate School Dean’s Fellowship.

After graduation, Wyndham furthered his training in stem cell biology and regenerative medicine as a Postdoctoral Fellow at the National Institutes of Health under Dr. Tiansen Li, where he learned to utilize functional biomaterials to direct the growth and behavior of human stem cell derived retinal organoids.

Wyndham now serves as the Senior Tissue Engineer at BE Therapeutics where he is developing novel biomaterial constructs for the creation of new functional brain tissue to be engrafted into damaged areas of the human brain.

SCIENTIST

Anna’s passion for neuroscience stems from her intrigue of how the biological building blocks in the brain give rise to complex thoughts and behaviors. To pursue this, she first received her BS in Neuroscience at New York University. During her undergraduate years, she conducted molecular neuroscience and behavioral research at New York University, the City University of New York, the University of Wisconsin, and Vanderbilt University. Her research was funded by fellowships from the National Science Foundation and the National Institutes of Health. Anna then received her PhD in Neuroscience from Johns Hopkins University.

During her doctoral work with Dr. Jeremiah Cohen, she used an interdisciplinary approach to combine electrophysiology, molecular biology, and behavior to further investigate the link between the brain and behavior. At BE Therapeutics, Anna is a Scientist with a focus on in vivo, behavioral, and electrophysiology research.

SCIENTIST

Monika was fascinated with regenerative medicine since she was an undergraduate student of Biotechnology in Szczecin, Poland. Her fascination with soft tissue engineering led her into multiple internships, including Wageningen University in the Netherlands, Polish Academy of Sciences, and Warsaw University of Technology. Monika focused on mastering biological approaches combined with biomaterials and precise deposition by 3D bioprinting. Monika’s PhD work at the Pennsylvania State University under professorship of Dr. Jeffrey Catchmark, was focused on innovative biomaterials and bioprinted functional pancreas-on-a-chip device.

After graduation Monika joined Biomics lab at CEA in Grenoble, France for a PostDoctoral project under mentorship of Prof. Xavier Gidrol, where she focused on PDAC initiation in a diabetic microenvironment. Following her interest in soft tissue engineering, Monika joined 3DBio Therapeutics company, where she was developing and translating innovative biological products and technologies from R&D to the clinic.

At BE Therapeutics, Monika is a Scientist with a focus on biomaterials development and vascularization in vivo for the neocortex repair.

Former FOUNDER & CSO Aug.2023-Jul2024

From as far back as he can remember, he has been fascinated by what we, as living creatures, are made of. When he learned early on that a single cell forms the whole human body following an innate genetic program, he became driven by how this process might be used to improve our biological fates and defeat aging.

This interest led him to do a Ph.D. in Genetics at the University of California, San Francisco, where with Dr. Gail Martin he studied the regulation of embryonic stem cell differentiation. Jean then moved to Stanford University for postdoctoral studies with Dr. Susan McConnell, where he focused on neural stem cells and how they generate the neocortex, the part of our brains that we use for our highest cognitive functions.

Jean is former Founder of BE Therapeutics and Professor of Neuroscience and Genetics at the Albert Einstein College of Medicine, where his lab focused on cell and tissue-based approaches to reverse brain aging.

In August 2024, Jean began program manager role at ARPA-H, tasked with enabling groundbreaking technologies and strategies to combat brain diseases.